The prevention of pneumococcal disease by vaccines: Promises and challenges

G. A. Poland

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

This article reviews the epidemiology of pneumococcal disease and the current data on pneumococcal vaccine efficacy, discusses promising new data regarding development of new protein-conjugate pneumococcal vaccines, and addresses controversies surrounding the widespread population use of these vaccines. Armed with these data, physicians, nurses, third party payers, and health care systems should develop systems and eliminate unintentional barriers so as to achieve widespread use of these life-saving vaccines. As history has demonstrated to us, control of pneumococcal disease is highly unlikely to occur from heavy investments in newer and ever more expensive antibiotics, as opposed to better methods of preventing disease through the rational and widespread population use of vaccines.

Original languageEnglish (US)
Pages (from-to)97-122
Number of pages26
JournalInfectious Disease Clinics of North America
Volume15
Issue number1
DOIs
StatePublished - 2001

Fingerprint

Pneumococcal Vaccines
Vaccines
Health Insurance Reimbursement
Conjugate Vaccines
Population
Epidemiology
History
Nurses
Anti-Bacterial Agents
Delivery of Health Care
Physicians
Proteins

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

The prevention of pneumococcal disease by vaccines : Promises and challenges. / Poland, G. A.

In: Infectious Disease Clinics of North America, Vol. 15, No. 1, 2001, p. 97-122.

Research output: Contribution to journalArticle

@article{1dddb6558cc548fab640f28224249c4f,
title = "The prevention of pneumococcal disease by vaccines: Promises and challenges",
abstract = "This article reviews the epidemiology of pneumococcal disease and the current data on pneumococcal vaccine efficacy, discusses promising new data regarding development of new protein-conjugate pneumococcal vaccines, and addresses controversies surrounding the widespread population use of these vaccines. Armed with these data, physicians, nurses, third party payers, and health care systems should develop systems and eliminate unintentional barriers so as to achieve widespread use of these life-saving vaccines. As history has demonstrated to us, control of pneumococcal disease is highly unlikely to occur from heavy investments in newer and ever more expensive antibiotics, as opposed to better methods of preventing disease through the rational and widespread population use of vaccines.",
author = "Poland, {G. A.}",
year = "2001",
doi = "10.1016/S0891-5520(05)70270-1",
language = "English (US)",
volume = "15",
pages = "97--122",
journal = "Infectious Disease Clinics of North America",
issn = "0891-5520",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - The prevention of pneumococcal disease by vaccines

T2 - Promises and challenges

AU - Poland, G. A.

PY - 2001

Y1 - 2001

N2 - This article reviews the epidemiology of pneumococcal disease and the current data on pneumococcal vaccine efficacy, discusses promising new data regarding development of new protein-conjugate pneumococcal vaccines, and addresses controversies surrounding the widespread population use of these vaccines. Armed with these data, physicians, nurses, third party payers, and health care systems should develop systems and eliminate unintentional barriers so as to achieve widespread use of these life-saving vaccines. As history has demonstrated to us, control of pneumococcal disease is highly unlikely to occur from heavy investments in newer and ever more expensive antibiotics, as opposed to better methods of preventing disease through the rational and widespread population use of vaccines.

AB - This article reviews the epidemiology of pneumococcal disease and the current data on pneumococcal vaccine efficacy, discusses promising new data regarding development of new protein-conjugate pneumococcal vaccines, and addresses controversies surrounding the widespread population use of these vaccines. Armed with these data, physicians, nurses, third party payers, and health care systems should develop systems and eliminate unintentional barriers so as to achieve widespread use of these life-saving vaccines. As history has demonstrated to us, control of pneumococcal disease is highly unlikely to occur from heavy investments in newer and ever more expensive antibiotics, as opposed to better methods of preventing disease through the rational and widespread population use of vaccines.

UR - http://www.scopus.com/inward/record.url?scp=0035062690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035062690&partnerID=8YFLogxK

U2 - 10.1016/S0891-5520(05)70270-1

DO - 10.1016/S0891-5520(05)70270-1

M3 - Article

C2 - 11301826

AN - SCOPUS:0035062690

VL - 15

SP - 97

EP - 122

JO - Infectious Disease Clinics of North America

JF - Infectious Disease Clinics of North America

SN - 0891-5520

IS - 1

ER -